Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H26N6O3 |
| Molecular Weight | 446.5016 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=NN4)C(O)=O)C(C)(C)O
InChI
InChIKey=VTRAEEWXHOVJFV-UHFFFAOYSA-N
InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)
| Molecular Formula | C24H26N6O3 |
| Molecular Weight | 446.5016 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Oral olmesartan medoxomil 10-40 mg once daily is recommended for the treatment of adult patients with hypertension, this dosage has consistently helped achieve a double-digit reduction both in systolic and diastolic blood pressure, a reduction which is maintained for one year. Extensive clinical evidence from several large well designed trials and the clinical practice setting has confirmed the antihypertensive efficacy and good tolerability profile of oral olmesartan medoxomil, as monotherapy in patients with hypertension. Olmesartan medoxomil has shown no clinically important pharmacokinetic interactions with digoxin, warfarin or antacid (aluminium magnesium hydroxide). Adverse events were infrequent in clinical studies of olmesartan medoxomil and were similar to those attributed to placebo.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic beta-adrenergic stimulation. | 2003 Jan |
|
| Mechanism of permeability-enhancing effect of EDTA and boric acid on the corneal penetration of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088). | 2005 Aug 11 |
|
| Self-association properties of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088), an antiglaucoma ophthalmic agent. | 2005 Aug 11 |
|
| Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. | 2005 Jul |
|
| Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. | 2007 Mar |
|
| Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan. | 2007 May |
|
| Improvement of stunned myocardium in dogs with olmesartan, an angiotensin II type 1 receptor antagonist, is independent of type 2 receptors. | 2008 |
|
| Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy? | 2008 Apr |
|
| Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model. | 2008 Dec |
|
| Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. | 2008 Sep |
|
| Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. | 2009 Apr |
|
| Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. | 2009 Jul |
|
| Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells. | 2009 Sep |
|
| Protective effects of angiotensin II type-1 receptor blockade with olmesartan on spinal cord ischemia-reperfusion injury: an experimental study on rats. | 2010 Aug |
|
| Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study. | 2011 Sep |
|
| Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. | 2012 May |
|
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | 2013 Dec |
|
| Modulation of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis by olmesartan and omega-3. | 2014 Jan 25 |
Patents
Sample Use Guides
BENICAR (olmesartan med oxomil) tablets dosage. Adult hypertension: Starting dose - 20 mg once daily (dose range 20 - 40 mg once daily). Pediatric hypertension (6 - 16 years): Starting dose for patients with body weight 20 to <35 kg - 10 mg once daily, if body weight >35 kg - 20 mg once daily (dose range 10 - 20 mg once daily and 20 - 40 mg once daily, respectively)
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Oct 21 21:29:26 UTC 2019
by
admin
on
Mon Oct 21 21:29:26 UTC 2019
|
| Record UNII |
8W1IQP3U10
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
C09DB02
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
||
|
NDF-RT |
N0000175561
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
||
|
NCI_THESAURUS |
C66930
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
||
|
LIVERTOX |
706
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
||
|
NDF-RT |
N0000000070
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL1516
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
C66253
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
144689-24-7
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
158781
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
OLMESARTAN
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
144689-24-7
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
321064
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | RxNorm | ||
|
591
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
8612
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
M8203
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | Merck Index | ||
|
SUB20707
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
C437965
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
144689-24-7
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY | |||
|
144689-24-7
Created by
admin on Mon Oct 21 21:29:26 UTC 2019 , Edited by admin on Mon Oct 21 21:29:26 UTC 2019
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR |
As there is almost a negligible accumulation of olmesartan ain the liver it is thought not to inhibit the production of eicosanoids.
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
As there is almost a negligible accumulation of olmesartan ain the liver it is thought not to inhibit the production of eicosanoids.
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY GENOTOXIC->PARENT |
NDMA is an organic chemical that is in a family of potent carcinogens.
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Probable human carcinogen.
|
||
|
IMPURITY -> PARENT |
Priority toxic pollutant.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||